Wegovy Hispanic / Latino Dose Adjustments: What the Evidence Actually Shows
Key numbers
- 2.4 mgRecommended weekly maintenance dose for weight reduction from week 17 in adultsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 13%Share of adults in the pooled 2.4 mg trials who were Hispanic or LatinoSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- minus 14.9%Mean weight change in STEP 1 adults without diabetes on semaglutide 2.4 mg at 68 weeksSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 6.5%Cardiovascular death, heart attack or stroke on semaglutide 2.4 mg in SELECT, versus 8.0% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Semaglutide
At a glance
- Ethnicity-specific dosing / none in the Wegovy label
- Standard titration / 0.25, 0.5, 1 and 1.7 mg in 4-week steps; from week 17 the recommended weight-reduction maintenance dose is 2.4 mg weekly, with 1.7 mg weekly also an option [1]
- Highest labeled dose / 7.2 mg weekly in adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss [1]
- Hispanic or Latino enrollment / 13% of adults in the pooled 2.4 mg weight-management trials; 5% of the 7.2 mg trial arm [1]
- Weight loss without diabetes / minus 14.9% vs minus 2.4% at 68 weeks in STEP 1 (N=1,961) [2]
- Weight loss with type 2 diabetes / minus 9.6% vs minus 3.4% at 68 weeks in STEP 2 (N=1,210) [3]
- Cardiovascular outcome / MACE 6.5% vs 8.0%, HR 0.80, in SELECT (N=17,604) [4]
- Most common adverse reactions / nausea 44% vs 16%, vomiting 24% vs 6% in the 2.4 mg trials [1]
Is there a Hispanic or Latino dose adjustment in the Wegovy label?
No. The Wegovy injection dosing section sets one weekly schedule: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance from week 17 [1]. From week 17, the recommended maintenance dose for weight reduction is 2.4 mg weekly; 1.7 mg weekly is also an option, and adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. The dosing section lists no adjustment based on ethnicity, race or ancestry. Wegovy tablets are a separate product form with their own daily titration: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg from day 91 [1].
The label's pharmacokinetic data also show no clinically significant differences in semaglutide exposure across eGFR 30 to under 90 or Child-Pugh A to C hepatic impairment [1]. For patients with diabetes, the label says to monitor blood glucose before and during treatment, and it notes that Wegovy produced less weight loss in people with type 2 diabetes than in those without [1].
Questions worth asking
What the trials show for Hispanic and Latino patients
Two kinds of numbers exist, and only one of them is about results.
Enrollment is reported. The label's safety data come from three placebo-controlled trials in 2,116 adults treated with Wegovy 2.4 mg injection for up to 68 weeks; 13% were Hispanic or Latino, 72% White, 14% Asian and 9% Black or African American [1]. In the two 72-week trials of the 7.2 mg dose, 5% of patients in the 7.2 mg arm were Hispanic or Latino [1]. Hispanic and Latino adults participated, but the reported results do not give their weight loss separately.
Results are reported for each trial as a whole. STEP 1, which enrolled 1,961 adults with obesity or overweight and no diabetes, found mean weight change of minus 14.9% with semaglutide 2.4 mg versus minus 2.4% with placebo at 68 weeks, and 86.4% versus 31.5% of participants lost at least 5% [2]. STEP 2, which enrolled 1,210 adults with type 2 diabetes, found minus 9.6% versus minus 3.4%, with at least 5% loss in 68.8% versus 28.5% [3]. STEP 5 followed 304 adults for 104 weeks and found minus 15.2% versus minus 2.6% [5]. That trial reported 93.1% of participants as White, a figure that does not show how many were Hispanic or Latino [5].
Type 2 diabetes and the Wegovy label
The label states that Wegovy produced less weight loss in patients with type 2 diabetes than in those without, and that the tablets were not studied for weight reduction in adults with type 2 diabetes [1]. The STEP 1 and STEP 2 averages above are separate trial-group figures.
The other diabetes-specific change on the label is hypoglycemia. In adults with type 2 diabetes and BMI 27 or more, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo, and the risk was higher with a sulfonylurea [1]. The label says to consider reducing the dose of insulin or an insulin secretagogue (such as a sulfonylurea) when starting Wegovy [1]. Adding Wegovy to insulin has not been evaluated [1].
Which dose adjustments the label does describe
- Escalation to 7.2 mg: for adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss; the pediatric maximum is 2.4 mg [1].
- Maintenance at 1.7 mg: an option for weight reduction and for cardiovascular risk reduction [1]; for MASH the dose is 2.4 mg and may be reduced to 1.7 mg [1].
- Missed doses: for a missed injection, the Wegovy label says the dose may be taken when the next scheduled dose is more than 2 days away; after 2 or more consecutive missed doses, the label says to re-escalate from a lower dose [1].
What to watch for during titration
Gastrointestinal reactions are the most common adverse reactions. In the pooled 2.4 mg trials, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; any gastrointestinal reaction occurred in 73% versus 47% [1]. Discontinuation for adverse reactions was 6.8% versus 3.2%, most often for nausea (1.8% versus 0.2%) and vomiting (1.2% versus 0%) [1]. Those figures are for the whole trial population.
Acute kidney injury from volume depletion occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in patients with prior renal impairment and during dose titration, often after gastrointestinal fluid loss [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion [1].
The boxed warning applies to all patients: semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, whether it does so in humans is unknown, and it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1].
Cardiovascular and liver indications
Wegovy injection is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to treat noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) [1]. The label's recommended dose for cardiovascular risk reduction is 2.4 mg (1.7 mg is an option), and for MASH it is 2.4 mg [1].
SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and BMI 27 or more but no diabetes. The composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo over a mean follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90) [4]. In ESSENCE, a planned week-72 interim analysis of the first 800 of 1,197 adults with MASH and fibrosis stage F2 or F3, resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% on 2.4 mg versus 34.3% on placebo [6].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is there a different Wegovy dose for Hispanic or Latino patients?
Do Hispanic and Latino patients lose less weight on Wegovy?
How many Hispanic or Latino adults were in the Wegovy trials?
Does type 2 diabetes change the expected weight loss?
Can the Wegovy dose go above 2.4 mg?
What does the label say about a missed Wegovy dose?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Wegovy injection and Wegovy tablets (Novo Nordisk) prescribing information. Wegovy injection and Wegovy tablets (Novo Nordisk) label
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
- Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
- Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099.